21.08.2017 23:59:52
|
JNJ To Pay Dearly For Talc-cancer Connection
(RTTNews) - Johnson & Johnson (JNJ) has been ordered to pay $417 million to a woman who claims to have developed ovarian cancer after using the company's talc products for feminine hygiene.
The Los Angeles Superior Court jury passed the verdict in favor of California resident Eva Echeverria. It is the largest award yet in a string of lawsuits alleging J&J failed to adequately warn customers about the risks of cancer by using its talc-based products.
The consumer goods company said it would appeal against the verdict. "We will appeal today's verdict because we are guided by the science, which supports the safety of Johnson's Baby Powder," J&J said.
The verdict includes $70 million in compensatory damages and $347 million in punitive damages.
"We are grateful for the jury's verdict on this matter and that Eva Echeverria was able to have her day in court," Mark Robinson, her lawyer, said in a statement.
J&J faces 4,800 similar cases nationally filed by women who alleges that they have developed cancer due to using the firm's products to address concerns about vaginal odor and moisture. The company has been hit with over $300 million in penalties in cases lost in Missouri.
The evidence around any link between talc use and cancer is inconclusive.
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Johnson & Johnsonmehr Nachrichten
12.02.25 |
Dow Jones 30 Industrial-Titel Johnson Johnson-Aktie: So viel Verlust wäre bei einem Investment in Johnson Johnson von vor einem Jahr angefallen (finanzen.at) | |
11.02.25 |
Börse New York: Dow Jones zeigt sich fester (finanzen.at) | |
07.02.25 |
Handel in New York: Dow Jones am Nachmittag in der Verlustzone (finanzen.at) | |
05.02.25 |
Dow Jones 30 Industrial-Papier Johnson Johnson-Aktie: So viel Gewinn hätte ein Investment in Johnson Johnson von vor 10 Jahren eingebracht (finanzen.at) | |
29.01.25 |
Dow Jones 30 Industrial-Papier Johnson Johnson-Aktie: Hätte sich ein Investment in Johnson Johnson vor 5 Jahren inzwischen rentiert? (finanzen.at) | |
28.01.25 |
Dienstagshandel in New York: Dow Jones schlussendlich in Grün (finanzen.at) | |
28.01.25 |
NYSE-Handel: Dow Jones verbucht Zuschläge (finanzen.at) | |
28.01.25 |
Freundlicher Handel: Dow Jones am Mittag mit Gewinnen (finanzen.at) |
Analysen zu Johnson & Johnsonmehr Analysen
Aktien in diesem Artikel
Johnson & Johnson | 150,44 | 0,72% |
|